RE:Big Pharma fight with generic companies for small moleculesBecause of the FDA's 12 year market exclusivity for an innovative biologial product, the combination of that new and innovative product, like ONCY's pelareorep, with one that is facing patent expiration, like many of the PD-(L)1 immune checkpoint inhibitors currently on the market, would then provide parallel protection for both products by virtue of the simple approval of the new and innovative product and then the specific immune checkpoint inhibitor that pelareorep would be paired with.
Such a specific combination would be extremely difficult to copy in a generic format.